Dopamine (DA) induction of the long-term enhancement (LTE) of the slow muscarinic depolarizing response to methacholine (MCh), equivalent to the slow EPSP (S-EPSP), was previously found to be mimicked by exogenous cyclic AMP (CAMP) in the rabbit superior cervical ganglion (SCG). DA-induced LTE of the S-EPSP was shown to be depressed by some DA antagonists. We now show that DA (15 PM), its analog, 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN), and a D, receptor antagonist, metoclopramide, each can induce both LTE of MCh depolarization and an increase in ganglionic CAMP. Conversely, antagonists of DAinduced LTE also depress DA-induced rises in CAMP; these antagonists include haloperidol (1 PM), both (+) and (-) enantiomers of butaclamol (0.7-7 AM), flupenthixol (1 FM), and (+)-R-6-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-l H-3-benzazepine-7-01 (SCH-23390) (7 PM). The selective D, antagonists sulpiride (10 PM) and domperidone (10 FM) affect neither DA action. Alpha-2 adrenergic agonists (cr-methylnorepinephrine and clonidine) produce no LTE; a-antagonist dihydroergotamine (35 PM) does not affect either DA action, although it can completely block the hyperpolarizing response to DA or other catecholamines. Beta-antagonist propranolol(5 PM) partially depresses DA-induced rises in CAMP but has no effect on the DA-induced LTE. (Butaclamol and propranolol in combination can completely block the CAMP rise induced by DA.) Beta-agonist isoproterenol can induce appreciable LTE of MCh depolarization, but this LTE is not depressed by propranolol(l0 PM). lsoproterenol can elicit a substantial rise in CAMP. We conclude that LTE of slow muscarinic depolarizing responses is induced via activation of a DA receptor that is coupled to adenylate cyclase and resembles, but is not identical to, D, receptors described in the brain. The induction of LTE by isoproterenol may reflect an ability to activate this DA receptor to some extent, rather than its additional activation of a #?-receptor. In contrast to
the CAMP produced at the DA receptor, CAMP formed via activation of &receptors in this ganglion appears to be ineffective for inducing LTE of muscarinic responses. Dopamine (DA) has been shown to induce in the rabbit sympathetic ganglia a long-lasting augmentation, continuing for hours, of the slow muscarinic depolarizing response to ACh or to the muscarinic agonists acetyl+methylcholine (MCh) and bethanechol (BCh) (Libet and Tosaka, 1970; Libet et al., 1975; Libet, 1979a) . The slow (s-) IPSP and s-EPSP elicited by orthodromic test volleys also exhibited a large augmentation following exposure of the ganglion to DA in the presence of an inhibitor of catechol-o-methyltransferase (COMT) 3',4'-dihydroxy-2-methylpropiophenone (U-052 1) (Ashe and Libet, 198 1) . A similar long-lasting change ("long-term enhancement" or LTE) of s-EPSP was seen after a conditioning train of preganglionic volleys, even when testing heterosynaptically in another unconditioned, preganglionic nerve Libet, 1983, 1985) . The ability, first, of DA to stimulate adenylate cyclase in sympathetic ganglia of at least some mammalian species (Kebabian and Greengard, 197 1; Wamsley et al., 1980) and, second, of CAMP, whether applied extracellularly (Libet et al., 1975) or intracellularly (Kobayashi et al., 1978) , to mimic the enhancing action of DA, led to the hypothesis that CAMP is the intracellular mediator of the neuronal change responsible for the DA-induced LTE (Libet et al., 1975; Libet, 1979b) . Pharmacological antagonists of DA receptors, particularly of D, type, were indeed found to selectively depress the DA-induced LTE (Ashe and Libet, 198 l) , as well as the neurally conditioned LTE of s-EPSP responses (Mochida and Libet, 1983) , while adrenergic antagonists were relatively ineffective.
The present investigation attempts to establish more definitely and specifically the identity of the postsynaptic receptors responsible for the DA induction of LTE of the slow muscarinic depolarization. The capabilities of various agonist and antagonist agents with respect to both actions of DA-the induction of LTE and the stimulation of adenylate cyclase (as indicated by changes in the ganglionic CAMP content)-were compared for the same superior cervical sympathetic ganglion in the rabbit. The results obtained provide evidence that both actions are due to the activation of one and the same kind of receptor, which resembles the D, type and is distinguished from D, as well as from LY-and &adrenergic receptors. Preliminary reports of this work have been presented in abstract form (Mochida et al., 1981a, b; Kobayashi et al., 1982) . 
Materials and Methods
Superior cervical ganglia (SCG) were excised from male white rabbits (weighing 1.8-2.2 kg) under light urethane anesthesia and placed in oxygenated modified Krebs solution with the following composition: NaCl, 136.0 mM, KCl, 5.94 mM, CaCl,, 2.54 mM, MgCl,, 1.2 mM, glucose, 11 .O mM, and Na-HEPES, 3.0 mM; pH 7.4. The connective tissue and the sheath surrounding the ganglion were carefully removed before all electrophysiological and biochemical studies. Electrophysiologi~al recordings and tests. Extracellular potentials were recorded using a sucrose-gap method (Kosterlitz et al., 1968; Wallis et al., 1975 ; modified by Libet and Tosaka, 1970; Libet et al., 1975) . The ganglion compartment, 0.3 ml, was perfused continuously with oxygenated Krebs solution at about 1 ml/min; o-tubocurarine, 30 &ml, was routinely present to minimize any nicotinic responses. The test response was the slow depolarization of the ganglion cells elicited by the muscarinic agonist MCh. MCh and other test agents were dissolved in a small volume (0.1 ml) of Krebs solution and rapidly injected into the line of perfusion at a point close to the chamber. The concentration of agents in the chamber after the injection was estimated by the following procedure, based on a simulation test (Tanaka, 1974) : The chamber (with no ganglion mounted) was perfused by distilled water at the same rate (1 ml/min) as in the actual experiments and known amounts (in micromoles per 0.1 ml) of KC1 were injected into the perfusion line. At 0.5, 1, 2, 5, and 10 min after the injection, 50 ~1 of perfusate in the chamber was sampled and the concentration of KC1 present, as determined by atomic absorption spectrophotometry, was consistently found to be, respectively, 2.1,6.2,3.6,2.0, and 0% ofthe concentration initially injected. The peak concentrations of other test substances in the chamber at 1 min were assumed to bear a similar relationship to that injected and were calculated accordingly. All recordings were made at room temperature (22-25°C).
Variable hyperpolarizing components may also be elicited by cholinergic agonists; changes in such hyperpolarizing components can produce corresponding changes in the form and amplitude of the slow muscarinic depolarization with which they overlap, thus complicating the results. An initial hyperpolarizing component, equivalent to the s-IPSP and largely attributable to the action of endogenous DA released from the small, intensely fluorescent (SIF) intemeurons (Libet, 1970; Libet and Tosaka, 1970; Libet and Owman, 1974) , could be eliminated by pretreating the ganglion with BCh (100 &ml for 15 min, followed by complete washout, then immersion in Krebs solution for about 90 min; Libet et al., 1975) . Such exposure to BCh depletes the functionally releasable DA from the SIF intemeurons and depresses the s-IPSP (Libet and Owman, 1974) . A later, secondary hyperpolarizing component, due possibly to the action of norepinephrine released dendritically from neighboring ganglion cells (Ashe and Libet, 1979; Libet, 1979a) could be eliminated by a pretreatment with bretylium: The drug was injected intravenously (4 mg/kg body weight) approximately 1 hr prior to the dissection of the ganglia and 6 &ml was further included in the bathing medium until the ganglion was mounted in the sucrose-gap chamber. With these combined pretreatments with BCh and bretylium, the depolarizing responses to the test application of MCh became more smoothly shaped, devoid of the above hyperpolarizing inflections.
Other minor inflections in the depolarizing responses to MCh, such as those visible in Figures 2 and 3 , are different from the large and changeable inflections that we refer to as initial and secondary hyperpolarization, which are removed by the treatments with BCh and bretylium. These minor inflections are presumably variables that are due to the rate of penetration of MCh into the surface neuronal elements in the ganglion and they do not change in any regular way with repeated tests or with the application of DA. Many responses to MCh show no such inflections at all, but still show the typical LTE following exposure to DA. Consequently, there is no evidence to support the possibility that the enhancement of the MCh depolarization is due to an elimination of hyperpolarizing components.
The LTE effect of DA on the muscarinic slow depolarization was observed by comparing the amplitudes of responses to a test dose of MCh before and at roughly 30 min intervals after a temporary exposure to DA. MCh doses were usually 50-100 pg in 0.1 ml, i.e., about 2.5-5 mM, producing peak concentrations of MCh in the chamber that were estimated to be 150-300 MM. The COMT inhibitor U-0521 (300 PM) was present in the perfusate starting 30 min in advance of the application of DA, continuing until 10-l 5 min after the DA. Although U-052 1 may have improved the consistency of the DA action on MCh depolarization, it was not essential for this (Libet and Tosaka, 1970) ; U-052 1 appears to be more essential when DA must penetrate to the larger number of the cells within the ganglion at 37°C as when testing for effects on surface-recorded s-EPSP (Ashe and Libet, 1981) and on the CAMP content of the whole ganglion. To avoid additional switching of perfusates, doses of DA (5 pg per 0.1 ml, or 250 PM concentration) were injected into the perfusion line 5 times at 2 min intervals; this procedure would produce and maintain an estimated concentration of DA of about 15 PM during the 8 min.
The DA-induced LTE process is a particularly labile one and was not exhibited by all ganglia tested (see Results) unless the following precautions were taken. It appeared more consistently when ganglia were kept well circulated with blood until the time of excision from the animal, and when the time spent in vitro before applying DA did not exceed 2-3 hr. Mechanical stretching or distortion of the ganglia had also to be avoided during excision, desheathing, and mounting in the chamber (Ashe and Libet, 198 1) . According to our present experience, paired ganglia excised from the same animal and treated as identically as possible tend to exhibit relatively similar enhancing effects from DA (see Results). Therefore, potential antagonists that might depress the DA-induced LTE action were always tested on such paired ganglia; i.e., the DA-induced change in MCh responses in the ganglion with antagonist present was compared to the DA effect in the paired control ganglion without antagonist. Those experiments in which the control ganglion itself did not show a substantial enhancement of MCh responses after the use of DA were discarded as inadequate tests of a depressant action by an antagonist.
Biochemical measurement of CAMP. To stabilize the CAMP levels at the baseline value, a set of paired ganglia, trimmed of pre-and postganglionic nerves, was left in the Krebs solution for 30 min after removing the sheath. To determine the baseline value, one of these ganglia was quickly frozen on the dry-ice/acetone immediately after this standing period. The other test ganglion was further preincubated at 37°C with theophylline (5 mM) for 30 min, after which U-052 1 (300 PM) was added. At the end of another 30 min, the ganglion additionally received DA and Na-ascorbate (6 x the DA concentration to minimize the oxidative destruction of DA during incubation) at the desired final concentration and was further incubated for another 30 min. Immediately afterwards, the ganglion was rapidly frozen. Both ganglia were homogenized with cold 6% trichloroacetic acid (TCA) and centrifuged for 25 min at 3500 rpm. After the TCA was removed from the supematant by shaking it with water-saturated ether, the supematant was lyophilized. It was later dissolved in 50 mM Tris/EDTA buffer and assayed for CAMP by means of the competitive protein-binding method of Gilman (1970) . Protein determination in the precipitates was made using the method of Lowry et al. (195 1) .
When observing the effects of various antagonists on CAMP synthesis, the increase in the member of the paired ganglia that was treated with DA in the presence of an antagonist, present since the time immediately after dissection, was compared with the baseline value in the contralateral ganglion (with no DA or antagonist) and was expressed as the percentage increase over the baseline value. The adequacy of the baseline value obtained from 1 of the paired ganglia with no additive drugs as the control for this series of experiments was demonstrated by further tests (Table 1) , which showed that (1) theophylline and ascorbate did not produce any appreciable change in the baseline value for the paired ganglia that were otherwise treated like the control ganglia above; (2) A '...~ U-0521 (in addition to the above additives) brought about only a small increase in CAMP content. The effect of (+)-butaclamol on this small increase was in the direction of at least partially depressing it. An absence of complete suppression could he due to the possibility that the increase was partly @-adrenergic in nature (see Discussion); (3) (+)-butaclamol (7 PM) by itself did not reduce the CAMP reference level of control ganglia in a nonspecific fashion. The statistical significance ofdifferences was determined, wherever necessary, by t tests. We are grateful for the sifts of the following materials: cu-methylnorepinephriie from Hoechsi AG, clonidine from Boehringer Ingeiheim, haloneridol from Dai-Ninuon Pharmaceutical Co.. sulniride from Fujisawa Pharmaceutical Co, domperidone from Janssen, (+)-and (-)-butaclamol from Ayerst Research Laboratories, flupenthixol (racemic form) from Take&t Pharmaceutical Co., dihydroergotamine from Sandoz, propranolol from Sumitomo Chemicals, U-0521 from Upjohn, bethanechol from Eizai Pharmaceutical Co., bretylium tosylate from Amar-Stone Laboratories, ADTN from Dr. G. N. Woodruff, University of Southampton, and SCH-23390 from Dr. A. Bamett, Schering-Plough Corp.
Results
Long-term enhancement (LTE) of muscarinic slow depolarization by DA and related substances Temporary exposure to DA produced a substantial increase in subsequent tests for slow depolarizing responses to MCh. In the tests with 167 pairs of ganglia, 124 (74%) exhibited an appreciable increase in the control side (subjected to the "standard" DA treatment; see Materials and Methods) of the pairs. In the rest (43 ganglia; 26%) no appreciable increase was observed. In those ganglia that produced no LTE, there appeared to be indications of a lack of necessary precautions (see Materials and Methods) to ensure the consistency of the DA effects. Any tests for the effectiveness of antagonists, etc., have therefore been performed only in ganglia whose paired counterparts (control sides) produced a substantial LTE. DA was tested at estimated concentrations (see Materials and Methods) between 0.3 and 150 PM (Fig. 1) . LTE was observed after treatment by DA above 1.5 PM. The degree of developed LTE was not linearly proportional to DA concentration, but rather exhibited a rapid rise to the maximum within a narrow range between 1.5 and 15 MM DA. Maximal enhancement of MCh depolarization was obtained with DA at 15 PM or more. U-052 1 alone did not produce appreciable enhancement of MCh depolarization as recorded in the sucrose gap (see also Materials and Methods), whereas it appeared capable of inducing a substantial LTE of orthodromic s-EPSP in the air gap (Ashe and Libet, 198 1) .
The degree of LTE of MCh test responses, expressed as the percentage increase over the amplitude of MCh depolarization before DA, was usually very similar for both ganglia of the pair excised from the same animal. In the experiments with 3 pairs of ganglia, both sides of a pair were identically treated by DA alone and the difference between increases in the amplitude of MCh depolarization in each of the 2 ganglia in a pair was determined. These differences produced a SEM of +-1.8%, with a normalization of each increase value in 1 side of the ganglia pair at lOO%, as illustrated in the top bar of Figure 4 ("No antagonist"). Actual increases with DA for different preparations, relative to the responses before DA, ranged from 20 to 100%. In 39 ganglia, the average increase of the MCh depolarization following exposure to DA (15 PM) was 69 f 9% (mean and SEM). The increased responsiveness to MCh fell off slowly (in repeated tests at 30 min intervals) over 3 hr or more (see also Libet and Tosaka, 1970; Libet et al., 1975; Libet, 1979a) .
The DA analog ADTN (2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene; Woodruff et al., 1979) consistently induced the LTE of MCh depolarization ( Fig. 2A) when administered in the same manner as DA. At an estimated concentration of 15 PM, the average increase in MCh depolarization was 49 Z!Z 4% in 3 experiments. When DA was tested on 1 of the paired ganglia and ADTN on the other, both at 15 PM, the LTE of MCh depolarization were roughly similar. ADTN tested in the absence of U-0521 (2 ganglia) induced LTEs roughly similar to those in the tests with U-052 1.
Metoclopramide is known to be an antagonist of the DA-D, receptor, the one not coupled to adenylate cyclase (Peringer et al., 1976; Roufogalis et al., 1976; Hyttel, 1978; Kebabian and Calne, 1979; Kebabian et al., 1984) . Surprisingly, exposure to metoclopramide at 50 PM (in the absence of U-052 1) was found to induce LTE of the orthodromically elicited s-EPSP response (Ashe and Libet, 1982a) . We also found in the present study that exposure to metoclopramide (50 I.LM for 15 min with no U-0521) was followed by a large LTE of the test response of MCh depolarization (Fig. 2B) ; average change in the MCh depolarization was + 8 1 f 4% for 3 experiments. (Other known D, antagonists-sulpiride, even at 60 PM, and domperidone at 10 r&r-had no enhancing or depressant effect on MCh depolarization; see below on Antagonists). The potent cr,-adrenergic agonists, cr-methylnorepinephrine (15 PM) and clonidine (15 PM), had no LTE effect at all on the MCh responses. However, p-adrenergic agonist isoproterenol (15 PM, tested either with or without U-052 1) appeared to have a definite enhancing effect on the MCh depolarization, although the evidence is not conclusive as to whether it is as effective as DA. Isoproterenol produced some enhancement in 9 out of 17 experiments. In 3 experiments, in which 1 paired ganglion was treated with DA and the other with isoproterenol (U-052 1 absent for both), enhancements were similar (about +88%) after 30 min; but the enhancement with isoproterenol fell off sharply thereafter, while that with DA remained high at 60 and 90 min.
Pharmacological antagonists of the DA-induced LTE of muscarinic depolarization DA induction of LTE of slow muscarinic depolarization was antagonized by certain neuroleptic drugs, but not by (Y-or p-antagonists. An example of the effects of (+)-butaclamol on the actual changes in MCh depolarization after DA is shown in Figure 3 . Results for experiments on similarly paired ganglia (both treated with DA but one in the presence of the antagonist drug) for all the other potential antagonists tested are summarized in Figure 4 . At the concentrations tested, none of the antagonists produced any significant depression of the depolarizing response to MCh itself. (The point was tested by observing the control MCh depolarization before and after adding an antagonist, and also in separate experiments with no exposure to DA, in which 1 ganglion of a pair received an antagonist and the subsequent MCh depolarization was compared for both ganglia.) The depressant effects shown in Figures 3 and 4 are thus specifically the reductions in the percentage of enhancement of MCh depolarization that follows exposure to DA in the paired ganglia without antagonists.
Fully adequate dose-response curves in the presence of each antagonist were not obtained, so that only crude inferences were made from the relatively small number of concentrations for the effectiveness of only (+)-butaclamol, which was found most effective among antagonists tested. It was almost fully (98%) effective at 7 PM (n = 4), still 61% effective at 0.7 PM (n = 2), 22% effective at 0.2 I.LM (n = 2), but showed no depressant effect at 0.07 PM (n = 2). The (-)-enantiomer of butaclamol was Other DA antagonists that also depressed the DA-induced LTE of MCh depolarization with an effectiveness roughly comparable to that of butaclamol were haloperidol and flupenthixol, when tested at 1 PM. R-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-lH-3-benzazepine-7-01 (SCH-23390), reported to be a potent and selective antagonist against D, receptors for DA in other tissues (Iorio et al., 1983; Goldberg et al., 1984; Kebabian et al., 1986) , appeared similarly effective. However, the relatively specific antagonists of D, receptors, sulpiride (Roufogalis et al., 1976; Kebabian and Calne, 1979) , and domperidone (Denef and Follebouckt, 1978; Kebabian et al., 1984) were completely ineffective even at 10 PM (Fig. 4) . Similarly, the cu-adrenergic antagonist dihydroergotamine (even at the high concentration of 35 KM) and P-antagonist propranolol (5 PM) had virtually no effect on the DA-induced change in MCh depolarization. Propranolol (even at 10 KM) did not depress the enhancing effect even of isoproterenol in 3 experiments.
Stimulation of ganglionic CAMP synthesis by DA and related substances CAMP content in one of the paired ganglia, simply after dissection from an animal and with 30 min stabilization, was found to be 21.42 + 1.25 pmol/mg protein (baseline value; n = 12). With 90 min incubation of counterpart test ganglion at 37°C with theophylline (5 mM), also with Na-ascorbate (300 PM) for the last 30 min, CAMP content was essentially unchanged (2 f 5% increase; y1= 3; see Table 1 ). With incubation with U-0521 (300 PM) for the last 60 min, together with the above theophylline and ascorbate, CAMP content showed only a small increase of 18 f 8% (n = 3), as opposed to the baseline value. This increase with U-0521 seemed at least partially depressed by butaclamol.
With 30 min incubation of the paired (test) ganglion in the medium containing various concentrations of DA (l-50 PM) and U-052 1 (as well as theophylline and Na-ascorbate; see Materials and Methods) at 37°C consistent and dose-dependent increases in the accumulation of intraganglionic CAMP were observed (Figs. 1 and 5 ). Maximal increase was attained at about 50 I.LM DA (68 + 5% over the baseline value; n = 12: The difference was statistically significant, with p < 0.001). At the much higher DA concentration of 200 PM, the increase in CAMP content fell off. ADTN, tested under similar conditions-at 10 PM with U-0521 present-induced a mean percentage increase in CAMP content over that of paired control ganglia: +35 f 14% (n = 4, p < 0.05). With U-0521 absent, ADTN at 50 PM could also induce an increase of 30 + 4% (n = 3, p < 0.001). Although this shows that U-052 1 is not essential in order for such agonists to stimulate adenylate cyclase, the values for ADTN and DA at 50 PM should not necessarily be regarded as indicating a difference in potency, since U-052 1 was present for DA throughout.
[ADTN is also a good substrate for COMT, according to G. N. Woodruff (personal communication) .] Isoproterenol, tested at 50 PM in the absence of U-052 1, also induced a substantial rise in CAMP content (mean percentage increase of + 37 f 4%; n = 3, p < 0.00 1). This is roughly similar to the increase with ADTN at 50 PM without U-0521 (see the Discussion).
Metoclopramide had been found in this study to induce an LTE of MCh depolarization, in a fashion similar to that of orthodromically produced s-EPSP responses (Ashe and Libet, 1982a) . It was also found here to increase CAMP content; with metoclopramide at 50 PM (without U-0521), the mean percentage increase in CAMP was +28 + 9% (n = 4, p < 0.001). Antagonists of the DA-stimulated synthesis of CAMP Those neuroleptic drugs that were shown to strongly antagonize the induction of LTE of MCh depolarization by DA were also shown to depress the elevation of ganglionic CAMP levels stimulated by DA (Fig. 6 ). Haloperidol (1 PM), (+)-and (-)-butaclam01 (7 PM), and flupenthixol (1 MM) all reduced the DAinduced increase in CAMP by about 50%; i.e., the mean increase of 68% following DA (50 PM) without antagonist was reduced to about 35% in the presence of each of such antagonists. SCH-23390 (7 FM) was tested in later, separate sets of experiments and was also found to depress a DA-induced increase in CAMP to about the same degree as did (+)-butaclamol. Sulpiride, domperidone, and dihydroergotamine, previously shown to be unable to prevent LTE of MCh depolarization by DA, were also relatively ineffective in depressing the DA-induced increase in CAMP.
On the other hand, propranolol(5 MM), although found to be ineffective against the LTE of MCh depolarization by DA, did block almost 50% of the DA-induced rise in CAMP. We postulate that propranolol was antagonizing mostly a p-adrenergic component of the DA-induced increase in CAMP, and that such a component accounted for the incomplete blockade by the neuroleptic drugs of the adenylate cyclase response to DA. To test the validity of this hypothesis for 2 different mediating receptors whose effects in increasing the CAMP content of the whole ganglion could be additive, we applied a combination of (+)-butaclamol (7 PM) and propranolol(5 PM). This combination of antagonists did in fact completely eliminate the DAinduced increase in CAMP. This latter result was shown to be not due simply to the need for a higher total concentration of et al. * CAMP and Dopamine-Induced Long-Term Synaptic Enhancement antagonists for maximal blockade of a single receptor; (+)-butaclamol alone raised to 15 PM (n = 4) was found to be no more effective than at 7 PM.
Discussion
The present investigation provides strong support for the view that modulatory long-term enhancement (LTE) of slow muscarinic responses by DA in the rabbit superior cervical ganglion is mediated by a specific DA receptor, in particular, one that is coupled to activation of adenylate cyclase (Libet et al., 1975; Kobayashi et al., 1978; Libet, 197913) . In the present experiments, both of the effects that follow exposure to DA (LTE of slow muscarinic depolarization and a rise in CAMP content) were studied in the same tissue and with similar concentrations of potential agonists and antagonists for both actions. As illustrated in Figure 1 , both of the above effects were shown to occur in the same range of DA concentration, but the dose-response curves for those 2 events were somewhat different in shape. Some differences in the experimental conditions for LTE tests and CAMP assays may help to account for the difference in the shapes of the dose-response curves: (1) LTE tests were performed at room temperature, while CAMP assays were at 37°C and (2) the penetration of DA deep into the ganglion may be required for a detectable increase in CAMP in the whole ganglion, while it is not essential for the LTE, as the electrical activities of only superficially located neurons are usually monitored in the sucrose-gap recording. Even with U-0521 alone, there was some increase of CAMP, while no LTE was produced (Fig. 1) . This discrepancy may be due particularly to the differences in temperature between the above 2 types of experiments. At room temperature, the spontaneous release of endogenous DA would be negligible and therefore U-052 1 alone would not help to increase CAMP content and to induce LTE. At a concentration of exogenous DA between 1 and 5 PM, CAMP started to increase further beyond the level with U-0521 alone. This may correspond to the fact that U-052 1 alone was able to induce some LTE of orthodromic s-EPSP in the air-gap experiments (which were carried out at 37"C), and exogeneous DA (50 PM) caused a further increase in the s-EPSP (Ashe and Libet, 198 1) . In the same range of DA as above, the LTE of MCh depolarization became evident (Fig. 1) . This agreement in the effective concentration, in spite of the difference in temperature, may support the view that the exogenously applied DA would induce the LTE by stimulating adenylate cyclase. Another characteristic difference in the shape of dose-response curves in Figure 1 may reflect differences in the cellular mechanism of the LTE and CAMP increases: It is possible that DA can stimulate the production of more CAMP than is necessary for a maximal LTE. This would make the DA concentration for the half-maximal increase in CAMP greater than that for the half-maximal induction of LTE. Furthermore, our findings in the present study that about a half of the DA stimulation of CAMP may be due to DA action on ,&adrenergic receptors, and may not be related to LTE, would also account for the difference in the two doseresponse curves in Figure 1 . Those agonists found to be effective for LTE of MCh depolarization were also capable of inducing a substantial rise in CAMP content; they were DA, ADTN, and metoclopramide. Conversely, those antagonist drugs that depressed the DA-induced LTE of MCh depolarization were also found to be capable of depressing the DA-induced rise in CAMP content; these ineluded butaclamol, haloperidol, flupenthixol, and SCH-23390, all regarded as antagonists of specific DA receptors (Seeman, 1980; Kebabian et al., 1986) . The inability of these agents to suppress the increase in CAMP as fully as they did the LTE of MCh depolarization is discussed below, with p-adrenergic actions. A discrepancy between the ability of propranolol to depress about a half of the increase in CAMP and its complete inability to depress the LTE will also be discussed. Antagonists of cu-adrenergic receptors (dihydroergotamine) and those more selectively antagonistic to the D, receptor (sulpiride and domperidone) were without effect on either of the DA actions under study.
DA can also induce a direct postsynaptic hyperpolarizing response during application to the ganglion (as previously shown for DA by Libet and Tosaka, 1970; Dun and Nishi, 1974) . This action is mediated by cu,-adrenergic receptors Mochida et al., 198 la; Ashe and Libet, 1982b ) and appears to be unrelated to DA induction of LTE for muscarinic slow depolarizing responses: (1) The hyperpolarizing response is over within a few minutes, long before the next test with MCh; (2) the enhancing effect is obtainable with lower doses of DA that elicit no hyperpolarization at all (Libet and Tosaka, 1970) ; (3) neither cu-methylnorepinephrine nor clonidine (15 PM) produced any enhancement of MCh depolarization, even though they can elicit a large hyperpolarizing response; and (4) metoclopramide (50 PM) produced no hyperpolarization but did induce enhancement of MCh depolarization.
The DA receptor mediating the LTE action of DA in the rabbit SCG resembles, but appears not to be identical with, the D, type described for striatal tissue in the brain (Hyttel, 1978 (Hyttel, , 1983 Kebabian and Calne, 1979; Seeman, 1980; Kebabian et al., 1984) . Like the brain receptor, the DA receptor in these ganglia is coupled to activation of adenylate cyclase, and antagonists of such an activation in the striatum also antagonize both the stimulation of adenylate cyclase and the enhancement of MCh depolarization by DA in the SCG. These include the antagonist SCH-23390, which, although highly selective for D, receptors in the brain (Iorio et al., 1983; Kebabian et al., 1986) , is actually no more potent than some of the mixed D,/D, antagonists (including haloperidol at 1 PM) against the DA cyclase effect (Hyttel, 1983) , as is the case with ganglia. Selective D, antagonists (sulpiride and domperidone) did not depress DA actions in ganglia. Metoclopramide, at a 10 PM concentration that is effective as a D, antagonist in brain tissue, also had no effect on DA-induced LTE (Ashe and Libet, 1982a) ; at higher concentrations, it behaved like an agonist (see below). On the other hand, the ganglionic DA receptor exhibits some properties at variance with those described for the striatal D, receptor: (1) The ganglionic receptor shows no stereoscopic specificity for the (+)-as opposed to the (-)-isomer of butaclamol, whether in testing DA induction of LTE for MCh depolarization (and for orthodromic s-EPSP responses; Ashe and Libet, 198 1) or in testing DA stimulation of adenylate cyclase. This contrasts with the sharp stereospecificity found in the striatum, etc. (Lippmann et al., 1975; Miller et al., 1975; Hyttel, 1978) . A similar absence of stereospecificity for butaclamol was shown for the inhibition of ATP-dependent 'H-DA binding in bovine caudatum at about 7 PM, a concentration similar to that used in the present study (Near and Mahler, 1982) . However, it was claimed that this DA binding was unrelated to the activation of adenylate cyclase, in contrast to our present results, which show a suppression of DA activation of adenylate cyclase by either stereoisomer of butaclamol. (2) Metoclopramide in higher concentrations (50 PM or more) mimics both of the DA actions in ganglia; but metoclopramide did not activate adenylate cyclase in the striatum, even at 50-200 PM (Roufogalis et al., 1976) . (3) The P-agonist isoproterenol appears to be able to activate the ganglionic DA receptor (see below); we do not know whether such an ability has been excluded for the striatal D, receptor. Whether D, receptors, with somewhat different features from the ganglionic one, also exist in some other, as yet untested, cerebral structures is presently an open question.
The issue of any potential role for a /3-adrenergic receptor in the ganglion is a complicated one and can lead to misinterpretations about the role of DA as well. The stimulation of adenylate cyclase via a P-receptor in the sympathetic ganglia of rats was already well known (Cramer et al., 1973; Lindl and Cramer, 1975; Lindl, 1979) . Those studies were done with no COMT inhibitor present; this may in part account for their inability to find substantial rises in CAMP with DA. DA presumably acts on postsynaptic D,-like receptors protected by COMT (Ashe and Libet, 198 l) , while some large part of the p-action may possibly be exerted through the P-receptors on non-neuronal elements, like satellite cells (Ariano et al., 1982) which may not have significant COMT barriers. While DA in the absence of COMT inhibitor did induce large increases in CAMP in slices of bovine SCG (Kebabian and Greengard, 197 1; Roth and Kalix, 1975) very small or almost no increases have been reported for DA applied to whole SCGs of rat (Cramer et al., 1973; Lindl, 1979) or rabbit (Kalix et al., 1974) . The larger increase in CAMP content with 50 KM DA than with 5 PM DA, 50 PM ADTN, or isoproterenol may suggest that both DA-specific and /3-adrenergic actions are additively involved in the action of higher concentrations of DA on adenylate cyclase in the rabbit SCG. In fact, approximately 50% of the rise in CAMP following 50 MM DA, with U-0521 present, was resistant to the DA antagonists but could be eliminated by the further addition of the P-antagonist propranolol (Fig. 6) . It appears, then, DA can activate the p-as well as "D," receptor in this tissue. Wamsley et al. (1980) had found that DA could elicit a substantial increase in CAMP content of the whole rabbit SCG, without having COMT inhibitor present (see also Williams et al., 1980) ; the present evidence suggests the possibility that some large fraction of that increase in CAMP by DA may have been mediated via a P-receptor, as Wamsley et al. (1980) apparently did not subject that DA effect to the P-antagonist propranolol. Conclusions based on findings of relative ineffectiveness of DA in stimulating adenylate cyclase must be reviewed in relation to (1) the need for a COMT inhibitor for adequate access to postsynaptic D, receptors (see also Ashe and Libet, 1981) and (2) the potential ability of DA to activate P-receptors in ganglia or other neural structures Isoproterenol appeared to produce some L'l E of muscarinic slow depolarization. However, since propranolol had no effect on this LTE action by isoproterenol (or by DA), the action is presumably not mediated by the P-receptor. This contrasts with a &receptor-mediated facilitation of ganglionic transmission in rat SCG (Brown and Dunn, 1983) and also with a @-adrenergic long-term facilitation of peptidergic transmission in guinea-pig inferior mesenteric ganglia (Dun et al., 1984) ; both effects were evidently blocked by propranolol. Instead, one might suggest that isoproterenol can, at least to some degree, activate the postsynaptic D,-type receptor in the rabbit SCG, just as DA (at 50 PM) appears able to activate a &receptor here. (Future testing of DA antagonists, like butaclamol, against isoproterenol-induced LTE would help to clarify this issue further.) It may be worth noting further that isoproterenol can also activate the LYEadrenergic receptor in ganglia and induce a hyperpolarizing response (Mochida et al., 198 la) . That the multiple effects of DA and isoproterenol thus observed are not all on a single receptor is indicated by the differential effects of DA versus P-antagonists for each component of action.
From the foregoing lines of evidence, one may conclude that it is specifically the DA receptor coupled to adenylate cyclase that mediates the LTE action by DA on the muscarinic postsynaptic responses, and that the P-receptor does not mediate this LTE, even though its activation also leads to an increase in ganglionic CAMP. While CAMP derived via the DA receptor would mediate the LTE process (Libet et al., 1975; Kobayashi et al., 1978; Libet, 1979b) , the CAMP derived from p-activation would be ineffective. The latter could be explained if the P-receptors were located on non-neuronal elements; or, if they were located on ganglion cells, the CAMP so produced might be sequestered and not have access to the intracellular sites that mediate the enduring change in muscarinic responsiveness. Previous suggestions that the DA-induced LTE action (Libet and Tosaka, 1970) and the DA stimulation of adenylate cyclase (Kebabian and Greengard, 197 1; Kalix et al., 1974) were mediated by an cY-adrenergic receptor were based on the depressant effects of phenoxybenzamine or on a high concentration of phentolamine; such effects by these antagonists can now be explained differently by an additional action, unrelated to the a-adrenergic antagonism (Walton et al., 1978) . Another a-antagonist, dihydroergotamine, even in relatively high concentrations had no effect on LTE or on CAMP increases by DA.
Although D, receptors (coupled to adenylate cyclase) are plentiful in certain cerebral structures (e.g., Miller et al., 1975; Kebabian and Calne, 1979) little is definitely known about their specific synaptic functions. The presently established role for such a receptor in the rabbit SCG offers a model for a modulatory role in synaptic transmission that could be tested for D, actions in the brain.
